Understand the source comparison
KPV Help Hashimoto's Research: Comparison of Evidence Strength
In vitro anti-inflammatory activity Confirmed. NF-κB inhibition demonstrated in multiple cell lines (UCLA 2019, Monash 2020) Hypothesized. Same pathways elevated in Hashimoto's but not directly tested Mechanism plausibility is high, but organ specificity unkno
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- In vitro anti-inflammatory activity
- Confirmed. NF-κB inhibition demonstrated in multiple cell lines (UCLA 2019, Monash 2020)
- Hypothesized. Same pathways elevated in Hashimoto's but not directly tested
- Mechanism plausibility is high, but organ specificity unknown
- Animal model efficacy
- Strong. 60% reduction in colonic inflammation in mice (10mg/kg oral, Monash 2020)
- None. No thyroid-specific animal studies published
- Cannot extrapolate gut outcomes to thyroid autoimmunity
- Human clinical trials
- None for any indication
- KPV remains investigational with no FDA approval or phase trials
- Thyroid antibody data
- Not applicable
- Not measured in any study
- Absence of TPOAb/TgAb endpoints is the critical gap
- Thyroid hormone data
- No TSH, T4, or T3 tracking means functional outcomes unknown
- Safety profile in humans
- Unknown. No published human dosing studies
- Long-term safety, dosing ranges, and contraindications undefined